Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients

被引:10
作者
Fogacci, Federica [1 ,2 ]
Giovannini, Marina [1 ,2 ]
Grandi, Elisa [1 ,2 ]
Imbalzano, Egidio [3 ]
Degli Esposti, Daniela [1 ,2 ]
Borghi, Claudio [1 ,2 ]
Cicero, Arrigo F. G. [1 ,2 ]
机构
[1] Univ Bologna, Med & Surg Sci Dept, Hypertens & Atherosclerosis Res Grp, Alma Mater Studiorum, I-40138 Bologna, Italy
[2] IRCCS Azienda Osped Univ Bologna, Cardiovasc Med Unit, I-40138 Bologna, Italy
[3] Univ Messina, Dept Clin & Expt Med, I-98122 Messina, Italy
关键词
cardiovascular risk; tailored medicine; hypercholesterolemia; LDL-C; PCSK9; inhibitors; LDL-C goal; CLINICAL-PRACTICE; DISEASE INSIGHTS; GUIDELINES; ATTAINMENT;
D O I
10.3390/jcm11164701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective and safe lipid-lowering treatments (LLT). The primary endpoint of the study was to assess the prevalence of patients eligible for treatment with PCSK9 inhibitors in a real-life clinical setting in Italy before and after the recent enlargement of reimbursement criteria. For this study, we consecutively considered the clinical record forms of 6231 outpatients consecutively admitted at the Lipid Clinic of the University Hospital of Bologna (Italy). Patients were stratified according to whether they were allowed or not allowed to access to treatment with PCSK9 inhibitors based on national prescription criteria and reimbursement rules issued by the Italian Medicines Agency (AIFA). According to the indications of the European Medicines Agency (EMA), 986 patients were candidates to treatment with PCSK9 inhibitors. However, following the prescription criteria issued by AIFA, only 180 patients were allowed to access to PCSK9 inhibitors before reimbursement criteria enlargement while 322 (+14.4%) with the current ones. Based on our observations, low-cost tailored therapeutic interventions for individual patients can significantly reduce the number of patients potentially needing treatment with PCSK9 inhibitors among those who are not allowed to access to the treatment. The application of enlarged reimbursement criteria for PCSK9 inhibitors could mildly improve possibility to adequately manage high-risk hypercholesterolemic subjects in the setting of an outpatient lipid clinic.
引用
收藏
页数:11
相关论文
共 33 条
[1]  
aifa, About us
[2]  
[Anonymous], about us
[3]   Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review [J].
Azari, Samad ;
Rezapour, Aziz ;
Omidi, Negar ;
Alipour, Vahid ;
Behzadifar, Masoud ;
Safari, Hossein ;
Tajdini, Masih ;
Bragazzi, Nicola Luigi .
HEART FAILURE REVIEWS, 2020, 25 (06) :1077-1088
[4]   Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel [J].
Banach, Maciej ;
Rizzo, Manfredi ;
Toth, Peter P. ;
Farnier, Michel ;
Davidson, Michael H. ;
Al-Rasadi, Khalid ;
Aronow, Wilbert S. ;
Athyros, Vasilis ;
Djuric, Dragan M. ;
Ezhov, Marat V. ;
Greenfield, Robert S. ;
Hovingh, G. Kees ;
Kostner, Karam ;
Serban, Corina ;
Lighezan, Daniel ;
Fras, Zlatko ;
Moriarty, Patrick M. ;
Muntner, Paul ;
Goudev, Assen ;
Ceska, Richard ;
Nicholls, Stephen J. ;
Broncel, Marlena ;
Nikolic, Dragana ;
Pella, Daniel ;
Puri, Raman ;
Rysz, Jacek ;
Wong, Nathan D. ;
Bajnok, Laszlo ;
Jones, Steven R. ;
Ray, Kausik K. ;
Mikhailidis, Dimitri P. .
ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) :1-23
[5]   Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia [J].
Banerjee, Yajnavalka ;
Pantea Stoian, Anca ;
Cicero, Arrigo Francesco Giuseppe ;
Fogacci, Federica ;
Nikolic, Dragana ;
Sachinidis, Alexandros ;
Rizvi, Ali A. ;
Janez, Andrej ;
Rizzo, Manfredi .
EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) :9-20
[6]  
Bonaca MP
[7]   Emerging drugs for the treatment of hypercholesterolemia [J].
Bove, Marilisa ;
Cicero, Arrigo F. G. ;
Borghi, Claudio .
EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) :63-69
[8]   Budget impact analysis of PCSK9 inhibitors costs from a community payers' perspective in Apulia, Italy [J].
Brunetti, Natale Daniele ;
De Gennaro, Luisa ;
Tricarico, Lucia ;
Caldarola, Pasquale .
OPEN HEART, 2019, 6 (02)
[9]   Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia [J].
Cicero, Arrigo F. G. ;
Fogacci, Federica ;
Cincione, Ivan .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (09) :1031-1037
[10]   Successful treatment of a patient with mitochondrial myopathy with alirocumab [J].
Cicero, Arrigo F. G. ;
Fogacci, Federica ;
Bove, Marilisa ;
Borghi, Claudio .
JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) :646-648